Baudax Bio Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Baudax Bio Inc (BXRX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Baudax Bio Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1M vs 2,118M combined for tracked competitors (0.1% combined share).
- Peer differentiation: Revenue per employee of $0.08M compares with $1.58M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Baudax Bio Inc vs. its Competitors, Q3 2023
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Baudax Bio Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Baudax Bio Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Baudax Bio Inc's competitor groups requires a Commercial License.
Baudax Bio Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Baudax Bio Inc | - | - | - | Yes |
| Competitors combined (5) | ||||
| High-Confidence Competitors (1) | - | - | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BXRX Stock Performance relative to its Competitors
BXRX Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Pacira Biosciences inc | 282.9% | Outperformed |
| 2 | Collegium Pharmaceutical Inc | 282.9% | Outperformed |
| 3 | Elite Pharmaceuticals Inc | 282.9% | Outperformed |
| 4 | Prf Technologies Ltd | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Baudax Bio Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Baudax Bio Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Baudax Bio Inc | 0.16 | 1.27 |
| Jll Income Property Trust Inc | 2,320.85 | 480.23 |
| Pacira Biosciences inc | 1,019.19 | 746.16 |
| Collegium Pharmaceutical Inc | 729.07 | 751.74 |
| Elite Pharmaceuticals Inc | 282.17 | 140.13 |
| Prf Technologies Ltd | 0.63 | 0.02 |
| SUBTOTAL | 4,352.07 | 2,119.55 |
Sources: Baudax Bio Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Baudax Bio Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Baudax Bio Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Trevena inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Baudax Bio Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Baudax Bio Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Jll Income Property Trust Inc | Residential 34.84 % |
| Pacira Biosciences inc | Reportable 100.00 % |
| Prf Technologies Ltd | Solar By Business Segments 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Baudax Bio Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Baudax Bio Inc | 0 | 79,313 | -447,187 |
| Jll Income Property Trust Inc | 2,321 | 28,248,765 | 687,176 |
| Pacira Biosciences inc | 1,019 | 900,077 | 17,657 |
| Collegium Pharmaceutical Inc | 729 | 1,777,173 | 113,274 |
| Elite Pharmaceuticals Inc | 282 | 2,155,840 | 871,815 |
| Prf Technologies Ltd | 1 | 2,429 | -717,429 |
| PEERS TOTAL | 4,352 | 1,579,630 | 93,871 |
Baudax Bio Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | -0.2x | 4.5x | -4.7x |
| Return on Equity | 54.54 % | industry aggregate | 43.08 % |
| Return on Invested Capital | 132.36 % | -2.95 % (avg) | 135.31 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Baudax Bio Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Revenue Growth | - | - | 7.04 % | 17.50 % |
| Operating Margin | - | - | -1,759.81 % | -4,476.99 % |
| Return on Invested Capital | - | -628.36 % | -39.50 % | -3,745.71 % |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Baudax Bio Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 43.1 points above the industry aggregate.
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-21.9% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Baudax Bio Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Baudax Bio Inc | 0.15 | 0.19 | - |
| Jll Income Property Trust Inc | 1.00 | 1.32 | 1.02 |
| Pacira Biosciences inc | 1.43 | 4.89 | 0.54 |
| Collegium Pharmaceutical Inc | 0.41 | 1.39 | 2.92 |
| Elite Pharmaceuticals Inc | 1.52 | 5.26 | 0.04 |
| Prf Technologies Ltd | 1.72 | 1.78 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Baudax Bio Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Baudax Bio Inc | Q3 2023 | - | - |
| Jll Income Property Trust Inc | Q2 2026 | +6.9 % | - |
| Pacira Biosciences inc | Q2 2026 | +6.2 % | - |
| Collegium Pharmaceutical Inc | Q2 2026 | +6.7 % | - |
| Elite Pharmaceuticals Inc | Q2 2026 | -17.5 % | - |
| Prf Technologies Ltd | Q4 2025 | - | - |
| PEERS TOTAL | +4.7 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Baudax Bio Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Baudax Bio Inc | Q3 2023 | -96.4 % | - |
| Jll Income Property Trust Inc | Q2 2026 | +5.5 % | +639.9 % |
| Pacira Biosciences inc | Q2 2026 | +8.1 % | -50.5 % |
| Collegium Pharmaceutical Inc | Q2 2026 | +47.1 % | +663.1 % |
| Elite Pharmaceuticals Inc | Q2 2026 | +57.1 % | +270.7 % |
| Prf Technologies Ltd | Q4 2025 | - | -84.6 % |
Baudax Bio Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Baudax Bio Inc | - | - | - |
| Jll Income Property Trust Inc | 0.21% | 0.21% | 0.61% |
| Pacira Biosciences inc | 1.17% | 1.29% | 2.13% |
| Collegium Pharmaceutical Inc | 2.72% | 3.72% | 15.96% |
| Elite Pharmaceuticals Inc | 46.11% | 53.48% | 71.10% |
| Prf Technologies Ltd | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Baudax Bio Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Baudax Bio Inc | - | 0.13 |
| Jll Income Property Trust Inc | - | 4.83 |
| Pacira Biosciences inc | 72.56 | 1.37 |
| Collegium Pharmaceutical Inc | 18.56 | 0.97 |
| Elite Pharmaceuticals Inc | 5.00 | 2.01 |
| Prf Technologies Ltd | - | 37.04 |
| PEERS AVERAGE | 36.66 | 2.05 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.